Two Experimental Drugs Targeting Parkinson’s Show Promise in 2026 Trials

Brenig Therapeutics has reported encouraging progress for two of its experimental therapies, BT-267 and BT-409, which are moving into crucial stages of clinical testing this year. The company’s latest data suggests that its lead candidate, BT-267, has successfully cleared one of the biggest hurdles in treating neurological conditions: getting the drug into the brain and keeping it there. BT-267 is designed to inhibit LRRK2, an enzyme that, when overactive, causes problems in the cell’s recycling and waste disposal systems. Genetic mutations in the LRRK2 gene are a known cause of Parkinson’s, but even people without this specific mutation may benefit from tamping down the enzyme’s activity. The challenge for scientists has always been creating a drug that can cross the protective blood-brain barrier effectively without causing unwanted side effects elsewhere in the body. Early results from healthy volunteers indicate that BT-267 does exactly that. The drug achieved high, sustained levels in the brain, reaching concentrations predicted to be effective for treating the condition. Based on this success, Brenig plans to launch a Phase 1b study later this year and is preparing for a Phase 2 proof-of-concept trial involving people with Parkinson’s in early 2026. Tien Dam, the company’s Chief Medical Officer, described the drug’s profile as potentially "best-in-class," noting that the strategy of optimizing brain penetration remains one of the most compelling ways to tackle the condition. While BT-267 targets the cellular machinery, the company’s second candidate takes aim at inflammation. Brenig has officially initiated a first-in-human study for BT-409, a drug designed to block NLRP3. This protein forms part of the "inflammasome," a complex that triggers chronic inflammation in the brain—a process believed to drive the progression of Parkinson’s. What makes BT-409 particularly interesting is its origin story. The molecule was discovered using an artificial intelligence platform aimed at solving the same puzzle: finding a compound that is potent, safe, and capable of entering the brain. If the initial safety trials in healthy volunteers go well, the company intends to test BT-409 in people with Parkinson’s as well as those with Multiple Sclerosis, another condition driven by neuroinflammation. Megan McGill, Brenig’s CEO, highlighted that the goal is to translate these scientific wins efficiently into the clinic. With one drug preparing to prove its worth in people with Parkinson’s and another entering human trials for the first time, 2026 is shaping up to be a busy year for the Boston-based biotech firm.